The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
Study Type
EXPANDED_ACCESS
Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.